Wednesday, November 18, 2020

Bumetanide to treat neonatal seizures

Soul JS, Bergin AM, Stopp C, Hayes B.  Singh A, Rosa Fortuno C, O'Reilly D, Krishnamoorthy K, Jensen FE.  Rofeberg V, Dong M, Vinks A, Wypij D, Staley K for the Boston Bumetanide Trial Group. A pilot randomized, controlled, double‐blind trial of bumetanide to treat neonatal seizures. Controlled bumetanide trial for neonatal seizures. Annals of Neurology |November 18, 2020

In the first trial to include a standard‐therapy control group, this study was undertaken to investigate bumetanide added to phenobarbital to treat neonatal seizures. Researchers randomized individuals with EEG‐confirmed seizures after ≥ 20 and < 40 mg/kg phenobarbital to receive additional phenobarbital with either placebo (control) or 0.1, 0.2, or 0.3mg/kg bumetanide (treatment). Individuals were assigned randomly to treatment (n=27) and control (n=16) groups. This randomized, controlled, multicenter trial indicated a drop in seizure burden that can be attributed to bumetanide over phenobarbital with no increase in serious adverse effects. Definitive proof of efficacy needs an appropriately powered phase 3 trial, and further evaluations of bumetanide and other drugs should include a control group and balance seizure severity.

Courtesy of:

No comments:

Post a Comment